Undertreatment and overtreatment with statins: The Oslo Health Study 2000-2001

Journal of Internal Medicine

Volumn 255, Issue 4, 2004, Pages 494-502

  Tonstad, S ^a   Rosvold, E O ^b   Furu, K ^b,c   Skurtveit, S ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Cardiovascular disease; Family history; Guidelines; Prevention; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DRUG UTILIZATION; FAMILY HISTORY; FEMALE; GENERAL PRACTITIONER; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NORWAY; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SECONDARY PREVENTION; SEX DIFFERENCE; STROKE;

EID: 1842506515     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01315.x     Document Type: Article

References (30)

1. http://www.slk.no/terapi/publiserte_terapi.htm.
2. Wood R, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 1995; 333: 1301-7.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
6. EURASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
7. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of 'statin' lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161: 53-8.
8. Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and women, a reflection of the research evidence? J Clin Epidemiol 2002; 55: 95-101.
9. Feely J, McGettingan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. Clin Pharmacol Ther 2000; 67: 438-41.
10. Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D. Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999; 21: 60-4.
11. Reid FD, Cook DG, Whincup PH. Use of statins to the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002; 88: 15-9.
12. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR. Cook DG. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 2003; 89: 417-21.
13. http://www.fhi.no/tema/helseundersokelse/pdf/eng_hovedo-slo.pdf.
14. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-62.
15. Vollset SE. Confidence intervals for a binomial proportion. Stat Med 1993; 12: 808-24.
16. Svilaas A, Ose L, Risberg K, Thoresen M. Treatment goals for blood lipids in high risk patients of atherosclerotic disease. Tidsskr Nor Lægeforen 2001; 121: 1059-63.
17. Sueta CA, Chowdhury M, Boccuzzi SJ et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303-7.
18. Bennett KE, Williams D, Feely J. Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland. Ir Med J 2002; 95: 169-72.
19. Furu K, Skurtveit S, Rosvold EO. Drug use questions in Norwegian health surveys - response rate and agreement between specific and open-ended questions. Nor J Epidemiol 2003; 13: 147-54.
20. West SL, Savitz DA, Koch G, Strom BL, Guess HA. Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142: 1103-12.
21. Kehoe R, Wu SY, Leske MC, Chylack LT. Comparing self-reported and physician-reported medical history. Am J Epidemiol 1994; 139: 813-8.
22. Graff-Iversen S, Grøtvedt L. Vekten øker, blodtrykket synker og 40-åringenes kolesterolnivå er som i 1991. Lipid forum 2003; 41: 14-9.
23. Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, Egger M. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990-2001. Heart 2003; 89: 327-8.
24. Shepherd J, Blauw GJ, Murphy MB et al. on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
25. Bønaa KH. Thelle DS. Association between blood pressure and serum lipids in a population: the Tromsa study. Circulation 1991; 83: 1305-14.
26. Conroy RM, Pyörälä K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
27. Haq IU, Ramsay LE, Yeo WW et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81: 40-6.
28. Hippisely-Cox J, Cater R, Pringle M, Coupland C. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 2003; 326: 689-92.
29. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-7.
30. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002; 53: 375-8.